Last reviewed · How we verify
NCT07225946: KLK2-PASenger
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 3 trial testing Pasritamig in Prostatic Neoplasms, Castration-Resistant in 800 participants. Currently enrolling.
19 November 2027
Quick facts
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 800 |
| Start date | 19 December 2025 |
| Primary completion | 19 November 2027 |
| Estimated completion | 20 July 2029 |
| Sites | 97 locations across France, Japan, Malaysia, Belgium, Taiwan, United Kingdom, South Korea, Canada |
Drugs / interventions tested
- Pasritamig — full drug profile →
- Docetaxel (Docetaxel) — full drug profile →
- Prednisone (prednisone) — full drug profile →
Conditions studied
- Prostatic Neoplasms, Castration-Resistant — all drugs for Prostatic Neoplasms, Castration-Resistant →
Sponsor
Janssen Research & Development, LLC — full company profile →
Who can join
18 and older, any sex, with Prostatic Neoplasms, Castration-Resistant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The path forward for T cell engagers in patients with prostate cancer.
Subudhi SK, Siddiqui BA, Zarrabi KK, Kelly WK, et al · · 2026 · PMID 41734994 · DOI 10.1136/jitc-2025-013905
Verify or expand the search:
- PubMed search for NCT07225946
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pasritamig
Trials testing the same drug.
- NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
- NCT07164443 — A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) · Phase 3 · recruiting
- NCT05818683 — A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer · Phase 1 · recruiting
Other recruiting trials for Prostatic Neoplasms, Castration-Resistant
Currently open trials in the same condition.
- NCT06706921 — 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer · Phase 4 · recruiting
- NCT06353386 — Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Particip · Phase 1, PHASE2 · recruiting
- NCT05743621 — Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer · Phase 1 · recruiting
- NCT05393791 — Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC · Phase 2 · recruiting
- NCT04597411 — Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer · Phase 1 · recruiting
Other Janssen Research & Development, LLC trials
Trials by the same sponsor.
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07225946 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07225946.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing